David A. Siegel Cardiol Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.88 - $2.06 $352 - $824	-400 Reduced 2.37%	16,500 $29,000
Q2 2023 Aug 14, 2023	SELL	$0.45 - $0.97 $2,475 - $5,335	-5,500 Reduced 24.55%	16,900 $15,000
Q1 2023 May 15, 2023	SELL	$0.47 - $0.81 $6,345 - $10,935	-13,500 Reduced 37.6%	22,400 $10,000
Q3 2022 Nov 14, 2022	SELL	$1.02 - $1.41 $27,132 - $37,506	-26,600 Reduced 42.56%	35,900 $37,000
Q2 2022 Aug 15, 2022	SELL	$1.03 - $2.05 $37,904 - $75,440	-36,800 Reduced 37.06%	62,500 $83,000
Q1 2022 May 16, 2022	SELL	$1.25 - $2.31 $30,375 - $56,133	-24,300 Reduced 19.66%	99,300 $152,000
Q4 2021 Feb 14, 2022	BUY	$1.83 - $4.86 $169,275 - $449,550	92,500 Added 297.43%	123,600 $229,000
Q3 2021 Nov 15, 2021	BUY	$2.03 - $4.8 $63,132 - $149,280	31,100 New	31,100 $129,000

5.47M

162K

7.4K

Ticker CRDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 61,942,500
Market Cap $123M
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.